Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

NCT ID: NCT07004413

Last Updated: 2025-06-04

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 267 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-01
• Study Completion Date: 2031-01-01

Brief Summary

The goal of this clinical trial is to learn if the application of the chemotherapy FOLFIRI and cetuximab works better when given with scheduled breaks or continuously in adults with metastatic colorectal cancer. The main question it aims to answer is, whether worsening of disease after 12 months of treatment is lower when the treatment is given with breaks or given continuously. It will also answer the question whether the quality of life is better and side effects are less if chemotherapy is given with breaks.

Additionally, the treatment breaks will be controlled by blood tests and imaging examinations. A novel blood test will be introduced to investigate, whether worsening of the disease might be detected before the imaging, and whether a quicker reaction by re-starting the therapy would help the patients.

Participants will:

• receive an established chemotherapy mit FOLFIRI and cetuximab
• Receive blood tests every 4 weeks and imaging investigations every 12 weeks
• fill out questionnaires to report their quality of life

Detailed Description

This is a combined multicenter, randomized phase III clinical trial and interventional clinical performance study according to IVDR investigating the superiority of intermittent application of FOLFIRI plus cetuximab followed by a scheduled treatment pause compared to continuous treatment with FOLFIRI plus cetuximab until disease progression or unacceptable toxicity. This study is accompanied by a translational research program.

This study protocol is driven by a CTR-conform question and primary endpoint, the PFS from randomization to progression on treatment at 12 months, and supplemented by a separate, complementary, interventional clinical performance study to assess ctDNA as biomarker of early disease progression as a key secondary endpoint. Details regarding the IVD part are specified in the complementary interventional clinical performance study protocol.

Treatment is planned until progression, death or unacceptable toxicity. Patients are followed up with regard to survival and if applicable subsequent anti - cancer treatments until death or -after end of study treatment- for at least 3 years after start of treatment, whichever date is earlier.

Conditions

Colorectal Cancer Metastatic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FOLFIRI+cetuximab, continuously applied

Continuous application of FOLFIRI+cetuximab until disease progression according to standard of care

Group Type: ACTIVE_COMPARATOR

FOLFIRI+cetuximab

Intervention Type: DRUG

Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.

FOLFIRI+cetuximab, applied with scheduled treatment breaks

Scheduled treatment break after up to 6 cycles of FOLFIRI+cetuximab until radiological (or, in part 2, ctDNA-based) disease progression

Group Type: EXPERIMENTAL

FOLFIRI+cetuximab

Intervention Type: DRUG

Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.

Guardant360 ctDNA assay

Intervention Type: DIAGNOSTIC_TEST

Determination of circulating tumor DNA (ctDNA) in the peripheral blood, part 1: retrospective threshold determination to predict radiological disease progression in Arm 2; part 2: prospective validation of the in part 1 identified ctDNA threshold to guide the scheduled treatment breaks and treatment in Arm 2

Interventions

FOLFIRI+cetuximab

Cetuximab 500 mg/m², 90 min IV infusion on d1; Irinotecan: 180 mg/m², 90-120 min IV infusion on d1; Folinic acid: 400mg/m², 1-2h IV Infusion on d1; 5-FU: 2400 mg/m², 46 h IV infusion on d1. Cycles are repeated on day 15.

Intervention Type: DRUG

Guardant360 ctDNA assay

Determination of circulating tumor DNA (ctDNA) in the peripheral blood, part 1: retrospective threshold determination to predict radiological disease progression in Arm 2; part 2: prospective validation of the in part 1 identified ctDNA threshold to guide the scheduled treatment breaks and treatment in Arm 2

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

Cetuximab, Irinotecan, Folinic acid, 5-fluorouracil (FU)

Eligibility Criteria

Inclusion Criteria

1. Patient's signed informed consent

2. Histologically confirmed, UICC stage IV unresectable adenocarcinoma of the colon or rectum

3. Locally confirmed RAS/BRAF wild-type tumor status (KRAS and NRAS exon 2, 3, 4, BRAF exon 11/15)

a) Note: A maximum of two cycles FOLFIRI is allowed prior to start of induction treatment until the molecular characterization is fully reported

4. Centrally confirmed RAS/BRAF wild-type status by liquid biopsy during screening phase

5. Age 18 or older at the time of written informed consent

6. ECOG performance status below or equal 1

7. Presence of at least one measurable reference lesion according to the RECIST 1.1 criteria

8. Archival tumor tissue available

9. Consent to storage, molecular and genetic profiling of tumor material and blood

10. Adequate bone marrow function:

1. Leukocytes ≥ 3.0 x 109/L with neutrophils ≥ 1.5 x 109/L

2. Thrombocytes ≥ 100 x 109/L

3. Hemoglobin ≥ 8 g/dL)

11. Adequate hepatic function:

1. Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)

2. ALAT and ASAT ≤ 2.5 x ULN (in the presence of hepatic metastases, ALAT and ASAT ≤ 5 x ULN)

3. INR < 1.5 and aPTT < 1.5 x ULN (patients without anticoagulation). Therapeutic anticoagulation is allowed if INR and aPTT have remained stable within the therapeutic range for at least 2 weeks.

12. Adequate renal function:

a) Creatinine clearance (calculated according to Cockcroft and Gault) ≥ 50 mL/min

13. Proficient fluorouracil metabolism as defined:

1. Prior treatment with 5-FU or capecitabine without unusual toxicity OR

2. If tested, normal DPD deficiency test according to the standard of the study site OR

3. If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%

14. Females of childbearing potential (FCBPs) and men must agree to use highly effective contraceptive measures (Pearl index <1) or practice true abstinence from any heterosexual intercourse (true abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject) for the duration of the study treatment and for at least 6 months after last administration of study medication. A woman will be considered as being of childbearing potential unless she is at least 50 years old and moreover has gone through menopause for at least 2 years or has been surgically sterilized. For men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo.

Exclusion Criteria

1. Proof of a RAS or BRAF mutation (KRAS/NRAS exons 2, 3, 4 or BRAF exon 15) in the tumor (proven in the primary tumor or metastasis) or liquid biopsy during screening phase.

2. Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before written informed consent.

3. New York Heart Association Class III or greater heart failure by clinical judgement.

4. Myocardial infarction, balloon angioplasty (PTCA) with or without stenting, and cerebral vascular accident/stroke within the past 12 months before randomization

5. Unstable angina pectoris

6. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic therapy.

7. Active uncontrolled infection by investigator's perspective.

8. Pre-existing pulmonary fibrosis or immune pneumonitis

9. Additional cancer treatment (chemotherapy, radiation, immunotherapy or hormone treatment) during the study treatment in first-line and third-line treatment (treatments that are conducted as part of an anthroposophical or homeopathic treatment approach, e.g. mistletoe therapy does not represent an exclusion criterion)

10. Participation in a clinical study or experimental drug treatment within 30 days prior to written informed consent or within a period of 5 half-lives of the substances administered in a clinical study or during an experimental drug treatment prior to written informed consent, depending on which period is longest or simultaneous participation in another study while taking part in the study

11. Known hypersensitivity or allergic reaction to any of the following substances: 5-fluorouracil, folinic acid, cetuximab, irinotecan and chemically related substances and/or hypersensitivity to any of the components in the formulations of the aforementioned substances, including known hypersensitivity reactions to monoclonal antibodies NCI CTC grade ≥ 3.

12. Known hypersensitivity to Chinese hamster ovary cell (CHO) -cellular products or other recombinant human or humanized monoclonal antibodies

13. Patients with known brain metastases or leptomeningeal disease. In case of clinical suspicion of brain metastasis, a cranial CT or MRI must be performed to rule out brain metastasis before study inclusion.

14. History of acute or subacute intestinal occlusion, inflammatory bowel disease, immune colitis or chronic diarrhea

15. Symptomatic peritoneal carcinosis

16. Severe, non-healing wounds, ulcers or bone fractures

17. Requirement for immunization with live vaccine including attenuated live vaccine from at least 4 weeks before begin of induction treatment until 6 months after the administration of IMPs.

18. Hemorrhagic diathesis or known thrombophilia

19. Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required)

20. Treatment with nucleoside analogues including sorivudine or brivudine within 28 days before begin of induction treatment or requirement for concomitant antiviral treatment with sorivudine or brivudine or analogues

21. History of a second primary malignancy during the past 5 years before written informed consent or during participation in the study, with the exception of a basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ, if these were treated curatively.

22. Active alcohol or drug abuse

23. Any significant adverse event that has not adequately resolved, severe acute or chronic concomitant disease or medical condition including psychiatric conditions (including recent i.e. within the past year or active suicidal ideation or behavior) or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

24. Absent or restricted legal capacity

25. Patients who are institutionalized by order of court or public authority

26. Patients who might be dependent on the sponsor/investigator or the trial site

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

UNKNOWN

Sponsor Role: collaborator

Guardant Health, Inc.

INDUSTRY

Sponsor Role: collaborator

Charite University, Berlin, Germany

OTHER

Sponsor Role: lead

Responsible Party

Sebastian Stintzing

Prof. Dr. med.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Charite University, Berlin

Berlin, , Germany

Countries

Germany

Central Contacts

Arndt Stahler, MD

Role: CONTACT

arndt.stahler@charite.de

+49 30 450 613 478

Facility Contacts

Arndt Stahler, MD

Role: primary

arndt.stahler@charite.de

+49 30 450 613 478

Other Identifiers

2025-522377-12-00

Identifier Type: CTIS

Identifier Source: secondary_id

AIO-KRK-0524

Identifier Type: OTHER

Identifier Source: secondary_id

U1111-1319-8357

Identifier Type: -

Identifier Source: org_study_id